The latest news on cancer diagnostics, liquid biopsy, and cancer risk testing.
Investigators plan to tap into large genomic and other datasets with an in silico patient to simulate drug responses, uncover treatment targets, and assess therapies.
A Myriad Genetics-funded team found that an 86-SNV polygenic score could modify breast cancer risk in women with pathogenic mutations in cancer risk genes.
The Cambridge, Massachusetts-based company recently reported positive interim results for the RET-targeting agent from the Phase I/II ARROW study.
In the Phase II TAPUR trial, palbociclib monotherapy demonstrated "modest antitumor activity" in heavily pretreated non-small cell lung cancer patients with CDKN2A alterations.
Bolt's lead candidate, BDC-1001, is an immune-stimulating antibody conjugate currently being studied in a Phase I clinical trial in HER2-expressing solid tumors.
